DRAP recall alert of “AMOXIL Suspension & AMOXIL forte Suspension”
DRAP RECALL ALERT OF “AMOXIL SUSPENSION AND AMOXIL FORTE SUSPENSION” due to complaint of Induction Seal. DRAP Alert No: II/V/08-25-53Date […]
Pharma Bulletin
FDA Seeks Public Opinion on Menopause Hormone Therapy Risks and Benefits
On July 17, 2025, the FDA brought together a panel of experts to discuss the benefits and risks of hormone
DRAP recall Substandard Medicines-27 June-2025
DRAP recall ⚠️Substandard Medicines⚕️-27 June-2025 The Directorate of Drug Control (DDC) Punjab has notify DRAP (drug regulatory authority of Pakistan)
DRAP Recall the Products Containing HYDROXYPROGESTERONE CAPROATE
DRAP RECALL ⚠️The PRODUCTS CONTAINING HYDROXYPROGESTERONE CAPROATE💉 DRAP (Drug regulatory authority of Pakistan has recalled and suspends the registration of
DRAP recall alert-23 June 2025
DRAP Recalls: Substandard Medicine : Famobex Suspension by Cibex (Pvt.) Ltd. The Drug Regulatory Authority of Pakistan (DRAP) has issued
Latest DRAP Recalls – June 2025 Drug Safety Update
DRAP Recall Alert⚠️Recall of Substandard “Tovir 0.5mg Tablet” having Batch No. 55, Manufactured by M/s Adamjee Pharmaceuticals (Pvt.) Ltd, Karachi.
FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma (FL)
FDA approves ✔️ Tafasitamab-cxix for relapsed or refractory follicular lymphoma (FL) On June 18, 2025, The FDA has approved tafasitamab-cxix
Meijer Issues Recall on Frederik’s Dark Chocolate Almonds Due to Presence of Undeclared Cashews
Meijer Issues Recall on Frederik’s Dark Chocolate Almonds Due to Presence of Undeclared Cashews GRAND RAPIDS, Mich. – Meijer has issued
DRAP’s action on Medroxyprogesterone acetate associated meningioma risk
DRAP’s Action on Medroxyprogesterone Acetate in Response to Meningioma Concerns and US Lawsuits Amid the ongoing lawsuits in the US
LATEST DRAP RECALL ALERT OF MEDICINES
DRAP RECALL ALERT-JUNE 2025 Drug regulatory authority of Pakistan (DRAP) is responsible for the regulation of drugs and therapeutic drugs
FDA Approves Darolutamide (NUBEQA®) For Metastatic Castration-Sensitive Prostate Cancer
FDA approves Darolutamide for metastatic castration-sensitive prostate cancer FDA approves darolutamide for metastatic castration-sensitive prostate cancer on june 3, 2025.
Pharmacovigilance via VigiMobile app- Smart Reporting.
VigiMobile app, a smart way to report ADR| Core of medical profession- essential to be known by every healthcare professional| Also get to known how to download the App.
Recall Alert-Homegrown Family Foods Issues Allergy Alert on Undeclared Milk in Shore Lunch Oven Style Breader & Batter Mix
Recall Alert-Homegrown Family Foods Issues Allergy Alert on Undeclared Milk in Shore Lunch Oven Style Breader & Batter Mix Homegrown